Abstract
BackgroundThe SURPRISE study is an open-label trial comparing the strategy of tocilizumab (TCZ) plus methotrexate (MTX) (ADD-ON) with the strategy of switching to TCZ (SWITCH) in Japanese rheumatoid arthritis (RA)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have